Envista Holdings Co. (NYSE:NVST – Free Report) – Leerink Partnrs increased their FY2024 earnings estimates for shares of Envista in a note issued to investors on Thursday, October 31st. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.70 per share for the year, up from their prior forecast of $0.68. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for Envista’s Q1 2025 earnings at $0.22 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.32 EPS and FY2026 earnings at $1.28 EPS.
Envista (NYSE:NVST – Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. Envista’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share.
View Our Latest Analysis on NVST
Envista Trading Down 0.1 %
NVST opened at $20.94 on Friday. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $25.64. The firm has a market capitalization of $3.60 billion, a PE ratio of -2.69 and a beta of 1.30. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.90. The company’s 50-day moving average is $18.64 and its 200 day moving average is $18.06.
Insider Buying and Selling
In other news, CFO Eric D. Hammes acquired 24,532 shares of Envista stock in a transaction on Monday, August 12th. The stock was acquired at an average cost of $16.33 per share, with a total value of $400,607.56. Following the completion of the acquisition, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Envista
Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Envista during the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC lifted its position in shares of Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after acquiring an additional 726 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after acquiring an additional 804 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Envista by 50.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after purchasing an additional 728 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock valued at $52,000 after purchasing an additional 2,940 shares in the last quarter.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
- Five stocks we like better than Envista
- How to Calculate Return on Investment (ROI)
- Battle of the Retailers: Who Comes Out on Top?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.